| This week's sponsor is FierceBiotech. | | | |
Today's Rundown Takeda strikes €520M deal to buy cell therapy firm TiGenix Johnson & Johnson pens Alzheimer’s gene therapy pact Deal-hungry Takeda hands over $150M to Denali for neurodegenerative work Former Receptos executives launch Gossamer Bio with $100M war chest China’s KBP gains GlaxoSmithKline executive as chief, an American headquarters and a cash boost Neurogastrx reels in $45M series A for gastroparesis med EuroBiotech Report—BioNTech megaround, Bristol-Myers backs Enterome, Boehringer VC, Pfizer-lTeos and Protalix FiercePharmaAsia—J&J-Legend CAR-T team-up, Eisai-Biogen Alzheimer’s flop, Impax’s deals Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune Featured Story | | | Friday, January 5, 2018 Takeda has put together a €520 million ($627 million) all-cash deal to acquire TiGenix. The takeover will give Takeda full control of Cx601, a stem cell therapy that is closing in on a European approval in Crohn’s disease. |
|
|
| This week's sponsor is Veeva. | | | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Top Stories Friday, January 5, 2018 Johnson & Johnson has formed an Alzheimer’s gene therapy research pact with the University of Pennsylvania. The partnership brings together J&J’s anti-Alzheimer’s antibodies and the university’s adeno-associated viruses in a bid to open up a new frontier in the fight against the disease. Friday, January 5, 2018 You remember reports a few years back of Takeda’s $15 billion M&A war chest for biotechs? Well, it hasn’t spent that much yet, but already this morning, and on the eve of J.P. Morgan, it’s struck two deals as it looks to make good on its ongoing R&D reorganization. Friday, January 5, 2018 Ex-Receptos CEO Faheem Hasnain has been keeping a low profile since selling the company to Celgene for $7.2 billion in 2015, but now he is back at the helm of a new biotech. Friday, January 5, 2018 KBP Biosciences has raised $76 million as it eyes a new headquarters in the U.S. and a new chief executive in the form of ex-GlaxoSmithKline veteran Brian McVeigh. Friday, January 5, 2018 Neurogastrx grabbed $45 million to bring its lead asset, a treatment for gastroparesis that targets the enteric nervous system, through proof of concept. Thursday, January 4, 2018 In this week's EuroBiotech Report, BioNTech raises $270 million, Bristol-Myers backs Enterome, Boehringer dials up its VC fund and more. Friday, January 5, 2018 Nanjing Legend Biotech partners with Johnson & Johnson to develop its CAR-T therapy, interim data from Eisai and Biogen's Alzheimer's candidate looks disappointing, Impax reaches a three-pronged deal with Taiwan's Bora Pharma and more. Friday, January 5, 2018 Jean-Paul Kress, M.D., jumped to Syntimmune after just six months with Biogen; Moderna now has biotech veteran John Mendlein, Ph.D., to guide its strategy; former FDA CIO and Takeda executive Eric Perakslis landed at Datavant; plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA Drug Approval, Manufacturing Quality & Regulation 2018 | Online Field Service Medical February 26-28, 2018 | Hilton La Jolla, Torrey Pines, CA |
